Cellular dosimetry of ¹⁹⁷Hg, ^197mHg and ¹¹¹In: comparison of dose deposition and identification of the cell and nuclear membrane as important targets

Adjuvant Auger Electron-Emitting Radioimmunotherapy with [111In]In-DOTA-Panitumumab in a Mouse Model of Local Recurrence and Metastatic Progression of Human Triple-Negative Breast Cancer

“…Emitting 19.4 to as many as 36.5 AE per decay, 197m Hg and 197 Hg, 201 Tl, 119 Sb, 193m Pt, and 195m Pt are promising alternative radionuclides for the design of more potent AE RIT agents . Indeed, cellular dosimetry calculations estimated an average of 2–3 fold higher energy deposition per decay for 197m Hg compared to 111 In (7.4 AE/decay), and novel bifunctional chelators for radiolabeling antibodies with 197m Hg have recently been reported …”

Ultrasmall Gold Nanoparticles Radiolabeled with Iodine-125 as Potential New Radiopharmaceutical

“…The emission spectra of 125 I obtained from the database MIRD (medical internal radiation dose) was used in this work . A nucleus radius of 5 μm and cell radius of 7 μm were used for the simulation of a single U87 cell . N.B.…”

Radiolabelled Cyclic Bisarylmercury: High Chemical and in vivo Stability for Theranostics

“…The emitted conversion electrons have energies closely corresponding with the beta emissions of 177 Lu used for therapy, [4] whilst a gamma emission is suitably near the energy of the 99m Tc gamma emission diagnostically used in single‐photon emission computed tomography (SPECT) medical imaging [5] . The high number of Auger electron (AE) emissions per decay ( 197m Hg: 19, 197 Hg: 23) also have great therapeutic potential, with similar energies to 125 I, which has already shown that even extracellular AE radiotherapy can effectively cause cell death [6–8] . Combined with the practical half‐lives of 23.82 h and 64.81 h (for the metastable and ground state nuclear isomers respectively) [9] and the stable 197 Au decay product, the innately theranostic nuclide 197(m) Hg is a promising candidate for radiopharmacy [10,11] …”

“… [5] The high number of Auger electron (AE) emissions per decay ( 197m Hg: 19, 197 Hg: 23) also have great therapeutic potential, with similar energies to 125 I, which has already shown that even extracellular AE radiotherapy can effectively cause cell death. [ 6 , 7 , 8 ] Combined with the practical half‐lives of 23.82 h and 64.81 h (for the metastable and ground state nuclear isomers respectively) [9] and the stable 197 Au decay product, the innately theranostic nuclide 197(m) Hg is a promising candidate for radiopharmacy. [ 10 , 11 ]…”

“…[5] The high number of Auger electron (AE) emissions per decay ( 197m Hg: 19,197 Hg: 23) also have great therapeutic potential, with similar energies to 125 I, which has already shown that even extracellular AE radiotherapy can effectively cause cell death. [6][7][8] Combined with the practical half-lives of 23.82 h and 64.81 h (for the metastable and ground state nuclear isomers respectively) [9] and the stable 197 Au decay product, the innately theranostic nuclide 197(m) Hg is a promising candidate for radiopharmacy. [10,11] There is historical precedence for the medicinal use of radiomercury, as during the 1960s and early 1970s reactor produced 197 Hg with low specific activity did see clinical use in diagnostics, for kidney and brain imaging, in the radiolabelled chlormerodrin, [12] a mercurial diuretic commercially traded from 1952 [13] till 1974.…”